2014 American Thyroid Association (ATA) Guidelines on
Thyroid Nodules and Differentiated Thyroid Cancer –
Highlights, Consensus, and Controversies
Friday, June 20, 2014, 12:30 PM-5:20 PM
McCormick Place

All current ATA Guidelines and Statements can be found on the ATA Guidelines page at: http://www.thyroid.org/thyroid-guidelines/

Program Description: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer (DTC) is becoming increasingly prevalent. A large amount of new information and evidence grading processes has become available since the 2009 guidelines. This has prompted the American Thyroid Association (ATA) to develop new and updated evidence-based recommendations to assist in the clinical management of patients with thyroid nodules and DTC. Authors from the international community of thyroid specialists in endocrinology and surgery will discuss recently published guidelines with special focus on:

  • Case based applications of the revised guidelines;
  • New guidelines in 2015; and
  • Contemporary optimal care for patients with thyroid nodules and differentiated thyroid cancer.
12:30 PM – 12:35 PM
Welcome and Introductions
Bryan R. Haugen, MD, University of Colorado School of Medicine
12:35 PM – 12:45 PM Process of Development and Format of the 2014 Nodules/DTC Guidelines
Bryan R. Haugen, MD
Approaches to Patients with Thyroid Nodules
12:45 PM – 1:00 PM Use of Neck Ultrasound to Guide Fine Needle Aspiration Decision-Making
Susan J. Mandel, MD, University of Pennsylvania
1:00 PM – 1:15 PM Cytologic and Surgical Pathology Considerations
Yuri Nikiforov, MD, PhD, University of Pittsburgh Medical Center
1:15 PM – 1:30 PM Use of Molecular Markers to Guide Decision-Making
David L. Steward, MD, University of Cincinnati
1:30 PM – 1:50 PM Questions and Answers
Approaches to Initial Therapy for Differentiated Thyroid Cancer
1:50 PM – 2:05 PM Preoperative Disease Mapping and Voice Assessment
Gregory W. Randolph, MD, Massachusetts Eye and Ear Infirmary
2:05 PM – 2:20 PM Surgical Approach and Considerations
Julie Ann Sosa, MD, Duke University School of Medicine
2:20 PM – 2:35 PM Staging and Risk Stratification Updates
Erik K. Alexander, MD, Brigham & Women’s Hospital
2:35 PM – 2:50 PM Updates on Radioactive Iodine Use – Consideration, Dosing, Preparation
Anna M. Sawka, MD, Toronto General Hospital
2:50 PM – 3:05 PM Integrating Response to Therapy in Monitoring Management
R. Michael Tuttle, MD, Memorial Sloan-Kettering Cancer Center
3:05 PM – 3:25 PM Questions and Answers
3:25 PM – 3:45 PM BREAK
Approaches to Patients with Advanced DTC
3:45 PM – 4:00 PM Monitoring and Directed Therapy for Radioactive Iodine-Refractory DTC
Furio Pacini, MD, University of Siena
4:00 PM – 4:15 PM Systemic Therapy and Clinical Trials for Radioactive Iodine-Refractory DTC
Keith C. Bible, MD., PhD, Mayo Clinic
4:15 PM – 4:30 PM Questions and Answers
4:30 PM – 5:20 PM Case-Based Discussion on Practical Applications of the 2014 Nodules/DTC Guidelines
Bryan R. Haugen, MD/Panel (comprised of speakers noted above)

Agenda for printing and Saving (PDF file, 139.79 KB)